ENB-0040
Phase 2Biologic
AstraZenecaENB-0040 is one of 11 biologic programs targeting Hypophosphatasia. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
13 competitors in Hypophosphatasia
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsApproved
Rituxan
RocheApproved
Folvite
Eli LillyApproved
Fosrenol
TakedaApproved
Velcade
SShilpa Grover, MD, MPH
Approved
Ivig
ArgenxApproved
STRENSIQ
AstraZenecaPhase 2
ALXN1850
AstraZenecaPhase 3
BPS804
UltragenyxPhase 2
ENB-0040
AstraZenecaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ENB-0040. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company